Rimegepant

What it is

Rimegepant is a small-molecule prescription drug that blocks the receptor for calcitonin gene-related peptide (CGRP), a nerve-signalling peptide involved in migraine attacks. In the United States it is sold as NURTEC ODT, an orally disintegrating tablet taken by mouth or placed under the tongue; each tablet delivers 75 mg of rimegepant free base. It is not a triptan and it does not constrict blood vessels. It is approved both to stop a migraine attack that has already started and, taken every other day, to reduce how often attacks happen.

What the research says

The strongest evidence is for stopping a single migraine attack: in placebo-controlled trials about one in five people were pain-free two hours after a 75 mg dose, compared with about one in ten on placebo, so the extra benefit over placebo is roughly 8 to 10 people in every 100 treated. A 2026 meta-analysis of seven trials put the number needed to treat at 10 for two-hour pain freedom. For prevention, a single 12-week trial found about 0.8 fewer migraine days per month than placebo. A 2024 network meta-analysis of 137 trials found several triptans were more effective than rimegepant for acute treatment. Tolerability in trials was close to placebo, with nausea the main difference; after marketing, hypertension and Raynaud's phenomenon were added to the label as warnings.

Evidence grade: Well established.

How it works

Drug class: Calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant")

Rimegepant blocks the receptor that CGRP binds to. CGRP is released around the trigeminal nerve and cranial blood vessels during a migraine attack and is thought to drive pain signalling and vessel dilation; blocking its receptor interrupts that signalling. Unlike triptans, gepants do not themselves constrict blood vessels, which is why they have been studied in people with cardiovascular risk. How this translates into the clinical effect is not fully worked out, and the label itself says the relationship between the drug's pharmacodynamic activity and its clinical effect is unknown. (Source 1)

What it is used for

• Several large double-blind placebo-controlled trials and a 2026 systematic review agree that a single 75 mg dose makes people more likely to be pain-free at two hours than placebo. The effect is real but modest: about 20% pain-free on drug versus about 11% on placebo, a number needed to treat of 10. Evidence: established. (Source 2)
• Approval rests on one 12-week phase 2/3 trial. 747 adults were randomised, 373 to rimegepant 75 mg every other day and 374 to placebo, and 348 and 347 were analysed for the Weeks 9 to 12 primary endpoint. Rimegepant beat placebo, but by 0.8 migraine days per month (-4.3 versus -3.5 days). No second confirmatory placebo-controlled trial of this regimen is in the label. Evidence: limited. (Source 3)
• The label states safety and effectiveness in children have not been established. The only published experience is a retrospective chart review of 12 adolescents at one centre, in which 10 of 12 reported improvement and no side effects were reported. That is a case series, not a trial. Evidence: limited. (Source 4)
• A 2026 scoping review of gepant pharmacology concluded that combining gepants with other migraine treatments is mechanistically plausible and supported by early pharmacokinetic and safety data, but that robust clinical trial evidence is still lacking. Evidence: limited. (Source 1)

Interactions

• Strong CYP3A4 inhibitors (for example itraconazole, ketoconazole, clarithromycin, ritonavir) (pharmacokinetic study): These drugs block the liver enzyme that clears rimegepant, so blood levels rise. In a dedicated interaction study itraconazole raised rimegepant exposure (AUC) about four-fold. The label says to avoid the combination. (Source 5)
• Strong CYP3A inducers (for example rifampicin, carbamazepine) (pharmacokinetic study): Inducers speed up clearance of rimegepant. Rifampicin cut rimegepant exposure by 80% in a dedicated study, which the label says may mean the drug stops working. (Source 6)
• St John's wort (Hypericum perforatum) (label): St John's wort is a well-known inducer of CYP3A, the enzyme that clears rimegepant. There is no published study of St John's wort with rimegepant specifically; the label's instruction is a class statement about strong and moderate CYP3A inducers, which is why this is listed as a label-level rather than a measured interaction. (Source 7)
• Potent P-glycoprotein inhibitors (amiodarone, cyclosporine, lapatinib, quinidine, ranolazine) (pharmacokinetic study): These block a transporter that moves rimegepant out of cells, raising exposure about 1.6-fold. The label says not to take another dose within 48 hours. (Source 8)
• Grapefruit juice (theoretical): Grapefruit juice inhibits CYP3A4 in the gut wall. No study has measured grapefruit juice with rimegepant, so this is an inference from the enzyme pathway plus the label's general instruction on moderate CYP3A4 inhibitors, not a measured interaction. (Source 9)
• Food, particularly a high-fat meal (pharmacokinetic study): Taking the tablet with a high-fat meal lowered peak blood levels by 41 to 53% and total exposure by 32 to 38%, and delayed the peak by about an hour. The trials dosed without regard to food, and the label says the effect of that drop on how well the drug works is unknown. (Source 10)

Stopping it

• Rimegepant is not a drug with a described withdrawal syndrome. The main stopping question for acute migraine drugs is medication-overuse headache. A 2026 scoping review of gepant pharmacology reported that preclinical and early clinical evidence points to a low likelihood of gepants causing medication-overuse headache, which is a weaker claim than a trial result. (Source 1)
• The label records an explicit limit on how much has been studied rather than a tapering schedule: the safety of more than 18 doses in 30 days has not been established. That is a statement about missing evidence, not a finding of harm above that number. (Source 11)
• In the postmarketing reports of Raynaud's phenomenon with CGRP antagonists, stopping the drug was followed by resolution of symptoms in most reported cases. These are spontaneous reports, so they cannot give a rate. (Source 12)

What goes wrong

Adverse events after a single dose were only slightly more common on rimegepant than placebo, 14.3% versus 12.7%, a difference that did not reach statistical significance. (Source 13)

• Meta-analysis, Moderate certainty.
• Size: 7 double-blind RCTs, 6,734 participants.
• Who: Adults treating a single migraine attack with 75 mg rimegepant or placebo.
• How long: Single dose, short-term follow-up.
• Result: Adverse events 14.3% vs 12.7% (RR 1.14, 95% CI 1.00-1.30, P=0.056, number needed to harm 55)
• Funding: not stated in the abstract.

Limit of this finding: The review's own arithmetic does not reconcile. From the percentages it prints, 19.8% versus 10.7% is a 9.1-point difference, which gives a number needed to treat of 11, not the 10 stated; 14.2% versus 6.3% gives 13, not the 11 stated; and 14.3% versus 12.7% gives a number needed to harm of 63, not the 55 stated. The stated risk ratios are also larger than the crude ratios of those percentages, which suggests the review derived its figures from pooled risk differences rather than from the percentages it reports, but it never says so. Treat the percentages as the reported data and the NNT and NNH figures as not checkable from them. Separately, the adverse-event result is not statistically significant: the interval touches 1.00 and p = 0.056.

AEs occurred in 14.3% of rimegepant-treated and 12.7% of placebo-treated participants (RR, 1.14; 95% CI, 1.00-1.30; P = 0.056; NNH = 55).

Nausea was the one adverse reaction clearly more common than placebo in the acute-treatment trial, 2% versus 0.4%; hypersensitivity including dyspnoea and severe rash occurred in under 1%. (Source 14)

• Official position, Certainty not rated.
• Size: 682 patients given one 75 mg dose in Study 1; long-term safety in 1,798 patients dosing for up to a year.
• Who: Adults with migraine; about 85% female, 74% White, 21% Black.
• How long: Single dose, with open-label extension up to one year.
• Result: Nausea 2% on NURTEC ODT vs 0.4% on placebo; hypersensitivity including dyspnea and severe rash in less than 1%.
• Funding: This is the manufacturer's FDA-approved label (DailyMed version 32, effective 4 June 2026), a regulatory position, not an independent analysis.

The most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo). Hypersensitivity, including dyspnea and severe rash, occurred in less than 1% of patients treated with NURTEC ODT

After marketing, new or worsening hypertension was reported with CGRP antagonists including rimegepant, some cases needing drug treatment or hospital admission. (Source 15)

• Official position, Very low certainty.
• Size: Not quantified; spontaneous postmarketing reports of uncertain denominator.
• Who: People taking CGRP antagonists after approval, some with pre-existing hypertension risk factors.
• How long: Most often reported within 7 days of starting.
• Result: No rate can be calculated. The label states cases required pharmacological treatment and, in some cases, hospitalization, and that onset was most frequently within 7 days of starting.
• Funding: Manufacturer label (DailyMed version 32, effective 4 June 2026); spontaneous reports cannot establish causation or frequency.

There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation.

New or worsening Raynaud's phenomenon has been reported with CGRP antagonists after marketing, with serious outcomes including hospitalisation and disability in many reported cases. (Source 12)

• Official position, Very low certainty.
• Size: Not quantified; spontaneous postmarketing reports.
• Who: People taking small-molecule CGRP antagonists, including those with pre-existing Raynaud's.
• How long: Median onset 1.5 days after dosing in reported cases.
• Result: Median symptom onset 1.5 days after dosing; many reports described serious outcomes including hospitalisations and disability, generally from debilitating pain.
• Funding: Manufacturer label (DailyMed version 32, effective 4 June 2026); spontaneous reports cannot give a rate.

In reported cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain.

Over a year of as-needed use, most people reported at least one adverse event of some kind, though few were judged drug-related and none were serious and drug-related. (Source 16)

• Randomized trial, Low certainty.
• Size: 240 participants treated, 208 (86.3%) completed.
• Who: Chinese adults with 6 to 18 moderate-to-severe migraine attacks per month.
• How long: 52 weeks of as-needed dosing, open-label single-arm.
• Result: 203 of 240 (84.6%) reported at least one treatment-emergent adverse event; 46 (19.2%) at least one considered rimegepant-related; no rimegepant-related serious adverse events and none leading to interruption or discontinuation.
• Funding: not stated in the abstract.

During LTT, 203 (84.6%) participants reported ≥1 treatment-emergent adverse event (TEAE) and 46 (19.2%) reported ≥1 TEAE considered to be rimegepant-related. There were no rimegepant-related serious AEs or rimegepant-related TEAEs that led to treatment interruption or discontinuation.

What the evidence supports

A single 75 mg rimegepant tablet made people more likely to be pain-free two hours after treating an attack than placebo, 19.6% versus 12.0%, an absolute difference of 7.6 percentage points. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 1,186 randomised; 1,072 evaluable for efficacy (537 rimegepant, 535 placebo)
• Who: Adults with at least a 1-year history of migraine and two to eight moderate or severe attacks per month; mean age 40.6 years, 88.7% women.
• How long: A single migraine attack, assessed to 2 hours (and to 48 hours for secondary endpoints)
• Result: Pain-free at 2 hours 19.6% vs 12.0% (absolute difference 7.6 percentage points; 95% CI 3.3 to 11.9; P<0.001); free of most bothersome symptom 37.6% vs 25.2% (absolute difference 12.4 percentage points; 95% CI 6.9 to 17.9; P<0.001)
• Funding: industry-funded (Biohaven Pharmaceuticals)

In a modified intention-to-treat analysis, the percentage of patients who were pain-free 2 hours after receiving the dose was 19.6% in the rimegepant group and 12.0% in the placebo group (absolute difference, 7.6 percentage points; 95% confidence interval [CI], 3.3 to 11.9; P<0.001).

The orally disintegrating tablet showed the same pattern: 21% pain-free at two hours versus 11% on placebo, a risk difference of 10 percentage points. (Source 17)

• Randomized trial, Moderate certainty.
• Size: 1,466 randomised; 1,351 evaluated for efficacy (669 rimegepant, 682 placebo)
• Who: Adults aged 18 or older with migraine of at least 1 year, treating a single attack of moderate or severe pain, 69 US centres.
• How long: A single attack, coprimary endpoints at 2 hours postdose.
• Result: Freedom from pain 21% vs 11% (p<0.0001; risk difference 10, 95% CI 6-14); freedom from most bothersome symptom 35% vs 27% (p=0.0009; risk difference 8, 95% CI 3-13)
• Funding: industry-funded (Biohaven Pharmaceuticals)

At 2 h postdose, rimegepant orally disintegrating tablet was superior to placebo for freedom from pain (21% vs 11%, p<0·0001; risk difference 10, 95% CI 6-14) and freedom from the most bothersome symptom (35% vs 27%, p=0·0009; risk difference 8, 95% CI 3-13).

A 2026 systematic review and meta-analysis of seven double-blind trials found 19.8% of people on rimegepant were pain-free at two hours versus 10.7% on placebo; the review states a number needed to treat of 10, which does not follow from those two percentages. (Source 13)

• Meta-analysis, Moderate certainty.
• Size: 7 double-blind RCTs, 6,734 participants.
• Who: Adults aged 18 or older with migraine with or without aura, given a single 75 mg oral dose.
• How long: Single attack; outcomes at 2 hours and sustained 2 to 24 hours.
• Result: Pain freedom at 2 h 19.8% vs 10.7% (RR 1.93, 95% CI 1.51-2.47, P<0.001, NNT 10); sustained pain freedom 2-24 h 14.2% vs 6.3% (RR 2.39, 95% CI 1.75-3.27, P<0.001, NNT 11)
• Funding: not stated in the abstract.

Limit of this finding: The review's own arithmetic does not reconcile. From the percentages it prints, 19.8% versus 10.7% is a 9.1-point difference, which gives a number needed to treat of 11, not the 10 stated; 14.2% versus 6.3% gives 13, not the 11 stated; and 14.3% versus 12.7% gives a number needed to harm of 63, not the 55 stated. The stated risk ratios are also larger than the crude ratios of those percentages, which suggests the review derived its figures from pooled risk differences rather than from the percentages it reports, but it never says so. Treat the percentages as the reported data and the NNT and NNH figures as not checkable from them. Separately, the adverse-event result is not statistically significant: the interval touches 1.00 and p = 0.056.

Two hours post-dose, 19.8% of participants receiving rimegepant and 10.7% receiving placebo achieved pain freedom (RR, 1.93; 95% CI, 1.51-2.47; P < 0.001; NNT = 10). Sustained pain freedom from 2 to 24 h was achieved by 14.2% of those receiving rimegepant, compared with 6.3% receiving placebo (RR, 2.39; 95% CI, 1.75-3.27; P < 0.001; NNT = 11). AEs occurred in 14.3% of rimegepant-treated and 12.7% of placebo-treated participants (RR, 1.14; 95% CI, 1.00-1.30; P = 0.056; NNH = 55). Risk of bias was judged as low across the included trials.

In the one published adolescent series, 10 of 12 teenagers reported their attacks resolved or improved and none reported side effects, but this is off-label use described in a retrospective chart review. (Source 4)

• Case series, Very low certainty.
• Size: 12 adolescents under 18 at a single centre.
• Who: Paediatric patients given at least one dose of rimegepant at Dell Children's Medical Center, 2020-2023; mean age 15.3 years, 75% female.
• How long: Retrospective chart review across clinic visits.
• Result: 10 of 12 (83%) reported resolution or improvement of attacks; no statistically significant changes in height, weight, blood pressure or laboratory values; no side effects reported.
• Funding: not stated in the abstract.

During follow-up, 10 of 12 (83%) patients reported either resolution or improvement of their migraine attacks with rimegepant use. There were no statistically significant height, weight, blood pressure, or laboratory changes after rimegepant use, and no patients reported side effects.

What the evidence does not support

In a network meta-analysis of 137 acute migraine trials, four triptans were more effective than rimegepant for stopping an attack. (Source 18)

• Meta-analysis, Moderate certainty.
• Size: 137 randomised controlled trials, 89,445 participants, 17 active interventions plus placebo.
• Who: Adults aged 18 or older with migraine diagnosed by the International Classification of Headache Disorders.
• How long: Single attack; pain freedom at 2 hours and sustained pain freedom 2 to 24 hours.
• Result: Eletriptan was the most effective for pain freedom at 2 hours (odds ratios from 1.46, 95% CI 1.18 to 1.81, to 3.01, 2.13 to 4.25), followed by rizatriptan, sumatriptan and zolmitriptan; the authors conclude these were more efficacious than lasmiditan, rimegepant and ubrogepant. CINeMA confidence ranged from high to very low.
• Funding: not stated in the abstract.

Limit of this finding: This passage is the authors' CONCLUSIONS section, not their results table. The recommendation that triptans 'should be considered as preferred acute treatment' and be added to the WHO List of Essential Medicines is the authors' interpretation of their network meta-analysis. The measured head-to-head results are recorded separately under rime-bmj-nma-2024-results.

Overall, eletriptan, rizatriptan, sumatriptan, and zolmitriptan had the best profiles and they were more efficacious than the recently marketed drugs lasmiditan, rimegepant, and ubrogepant.

In the 12-week prevention trial the overall rate of adverse events was identical on rimegepant and placebo, 36% in each group. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 741 participants in the safety analysis (370 rimegepant, 371 placebo)
• Who: Adults with migraine taking 75 mg every other day.
• How long: 12 weeks.
• Result: 133 (36%) of 370 on rimegepant reported an adverse event vs 133 (36%) of 371 on placebo; 7 (2%) vs 4 (1%) discontinued because of an adverse event; no deaths.
• Funding: industry-funded (Biohaven Pharmaceuticals)

133 (36%) of 370 patients who received rimegepant reported an adverse event, compared with 133 (36%) of 371 who received placebo.

Where the evidence is mixed

Taken every other day for 12 weeks, rimegepant reduced monthly migraine days by 0.8 days more than placebo. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 747 randomised (373 rimegepant, 374 placebo); 695 analysed for efficacy.
• Who: Adults with at least a 1-year history of migraine, 92 sites in the USA.
• How long: 4-week observation then 12 weeks double-blind; primary endpoint weeks 9-12.
• Result: Change in mean monthly migraine days weeks 9-12: -4.3 days (95% CI -4.8 to -3.9) with rimegepant vs -3.5 days (-4.0 to -3.0) with placebo; least squares mean difference -0.8 days (95% CI -1.46 to -0.20; p=0.0099)
• Funding: industry-funded (Biohaven Pharmaceuticals)

Limit of this finding: The regimen is not in the quoted sentence: it was oral rimegepant 75 mg or matching placebo every other day for 12 weeks, after a 4-week observation period. Note also that the trial randomised 373 and 374 people but the Weeks 9 to 12 efficacy analysis used 348 and 347; the effect size belongs to the smaller, analysed group.

The change from the observation period in mean number of migraine days per month during weeks 9-12 was -4·3 days (95% CI -4·8 to -3·9) with rimegepant and -3·5 days (-4·0 to -3·0) with placebo (least squares mean difference -0·8 days, 95% CI -1·46 to -0·20; p=0·0099).

Where the research disagrees

Whether rimegepant should be a first-choice drug for stopping a migraine attack, given how it compares with triptans

• Karlsson and colleagues, 2024 BMJ network meta-analysis of 137 trials, Network meta-analysis of 137 randomised trials in 89,445 participants, CINeMA confidence high to very low: the most effective triptans should be considered as preferred acute treatment for migraine and included in the WHO List of Essential Medicines to promote global accessibility and uniform standards of care. (Source 18)
• Authors of the 2026 rimegepant-specific systematic review and meta-analysis, Systematic review and meta-analysis of 7 double-blind RCTs, 6,734 participants, low risk of bias, GRADE applied; the authors position rimegepant for people who cannot use or did not respond to first- or second-line drugs: AEs occurred in 14.3% of rimegepant-treated and 12.7% of placebo-treated participants (RR, 1.14; 95% CI, 1.00-1.30 (Source 13)

How much

• Reference intake: There is no reference intake for a prescription drug. The dose is set by the prescriber. The FDA-approved label (DailyMed version 32, effective 4 June 2026) records, as a regulatory position, 75 mg as needed for an attack and 75 mg every other day for prevention, with or without food. (Source 11)
• Upper limit: The label's stated ceiling, again a regulatory position rather than a trial finding, is 75 mg in any 24-hour period, and it states that the safety of more than 18 doses in 30 days has not been established. (Source 11)
• Studied: The acute-treatment trials gave adults a single 75 mg dose to treat one attack of moderate or severe pain. (Source 19)
• Studied: The prevention trial randomised 373 adults to rimegepant 75 mg every other day and 374 to placebo for 12 weeks; the Weeks 9 to 12 efficacy analysis in the label's Table 3 used 348 and 347. (Source 20)
• Studied: A 52-week open-label study let 240 adults take up to one 75 mg tablet a day as needed. (Source 16)

A common belief, and what the research shows

The belief: Because rimegepant is a newer, targeted migraine drug, it must work better than older ones like triptans.

What the research shows: The head-to-head evidence points the other way. A 2024 network meta-analysis of 137 trials in 89,445 people reported that “eletriptan, rizatriptan, sumatriptan, and zolmitriptan had the best profiles and they were more efficacious than the recently marketed drugs lasmiditan, rimegepant, and ubrogepant”. What rimegepant offers is not greater efficacy but a different safety profile: gepants do not constrict blood vessels, and a 2026 review notes that “their lack of vasoconstrictive activity makes them suitable for patients with cardiovascular comorbidities”.

Questions and answers

What is it?

Rimegepant is a prescription tablet that blocks the receptor for calcitonin gene-related peptide, a peptide released by nerves during a migraine attack. In the US it is sold as NURTEC ODT, an orally disintegrating tablet containing 85.7 mg of rimegepant sulfate, equal to 75 mg of rimegepant free base. It can be placed under the tongue or swallowed. It is not a triptan and does not narrow blood vessels. (Source 21)

What does it do in the body?

CGRP is released around the trigeminal nerve and cranial vessels during a migraine attack and drives pain signalling. Rimegepant occupies the CGRP receptor so the peptide cannot signal. Because gepants have no vasoconstrictor action of their own, reviewers describe them as usable in people with heart or vascular disease in whom triptans are avoided. The exact link between this receptor blockade and the clinical effect has not been fully established. (Source 1)

Is it good or bad for you?

For adults treating a migraine attack the evidence supports a real but modest benefit: pooled across seven trials, about 20 in 100 were pain-free at two hours on rimegepant against about 11 in 100 on placebo, a number needed to treat of 10. Short-term tolerability is close to placebo. Against that, four triptans beat it in a network meta-analysis, and after marketing hypertension and Raynaud's phenomenon were added to its label. So it is a reasonable option, not a stronger drug than what came before. (Source 13)

How do you get more of it?

Rimegepant is a prescription-only synthetic drug. There is no food, supplement or behaviour that supplies it, and no over-the-counter version. The only way anyone has it is as the dispensed tablet. The label describes a 75 mg orally disintegrating tablet taken as needed for an attack, or every other day for prevention; the amount is set by a prescriber, not chosen by the person taking it. (Source 11)

If it is harmful, what reduces it?

If rimegepant causes a problem, the step described in the literature and the label is simply to stop taking it; there is no antidote and no tapering schedule. For the two postmarketing vascular warnings the label instructs discontinuation, and in reported Raynaud's cases stopping the CGRP antagonist was followed by symptoms resolving. For a hypersensitivity reaction the label says to discontinue and treat the reaction. (Source 12)

Why might someone be low in it or missing it?

Rimegepant is not something a body can be low in; it is a drug someone either takes or does not. Reasons a person might not be on it include it never having been prescribed, a previous hypersensitivity reaction, which is a contraindication, severe liver impairment, where exposure roughly doubles, or being under 18, where safety and effectiveness have not been established. Taking a strong CYP3A inducer can also leave blood levels too low to work. (Source 22)

Which whole foods contain it or feed it?

No whole food contains rimegepant. Food matters only in the opposite direction: it lowers the amount absorbed. A high-fat meal cut peak blood levels by 41 to 53% and total exposure by 32 to 38%, and a low-fat meal cut peak levels by 36%. The trials dosed without regard to food, and the label says the clinical effect of that reduction is unknown. Grapefruit juice is the food to be aware of, because it inhibits the enzyme that clears the drug. (Source 10)

What happens if you do not have it?

Not taking rimegepant causes no deficiency. The question is what is lost in benefit. Across seven trials the drug raised two-hour pain freedom from about 11% to about 20%, so roughly nine people in every hundred treated gain pain freedom they would not otherwise have had; the other ninety-one get the same result they would have had on placebo. Used as prevention, the gain was about 0.8 fewer migraine days a month than placebo. Plenty of other effective acute treatments exist, including several triptans that outperformed it in a network meta-analysis. (Source 3)

How can you test for it?

There is no blood test used to monitor rimegepant, and none is required by the label. Unlike the first-generation gepants, it was not associated with liver toxicity in trials: in the orally disintegrating tablet trial one person in each group had a transaminase above three times the upper limit of normal and neither was judged drug-related. What is monitored instead is clinical: blood pressure, because of the postmarketing hypertension reports, and symptoms of Raynaud's phenomenon. Liver function matters for dosing only in severe impairment, where exposure roughly doubles. (Source 17)

References

1. Headache. The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies.. 2026. PMID 42265882, DOI 10.1111/head.70114. Read the source
2. The New England journal of medicine. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.. 2019. PMID 31291516, DOI 10.1056/NEJMoa1811090. Read the source
3. Lancet (London, England). Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.. 2021. PMID 33338437, DOI 10.1016/S0140-6736(20)32544-7. Read the source
4. Headache. Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents.. 2026. PMID 41652664, DOI 10.1111/head.70033. Read the source
5. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
6. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
7. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
8. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
9. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
10. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
11. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
12. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
13. The journal of headache and pain. Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis.. 2026. PMID 42143245, DOI 10.1186/s10194-026-02388-x. Read the source
14. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
15. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
16. Cephalalgia : an international journal of headache. Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.. 2025. PMID 41066271, DOI 10.1177/03331024251371686. Read the source
17. Lancet (London, England). Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.. 2019. PMID 31311674, DOI 10.1016/S0140-6736(19)31606-X. Read the source
18. BMJ (Clinical research ed.). Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis (authors' conclusions). 2024. PMID 39293828, DOI 10.1136/bmj-2024-080107. Read the source
19. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
20. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
21. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source
22. Pfizer Laboratories Div Pfizer Inc / DailyMed (U.S. National Library of Medicine). NURTEC ODT (rimegepant sulfate) tablet, orally disintegrating - FDA prescribing information (DailyMed SPL, version 32). 2026. Read the source